桂枝茯苓丸治疗原发性痛经:随机对照试验
本研究为随机双盲安慰剂对照试验,纳入热灼血瘀证原发性痛经患者128例,随机分入桂枝茯苓丸组或安慰剂组,每日两次,治疗3个月经周期并随访3个月。结果显示,桂枝茯苓丸组在第6个月时VAS疼痛评分、CMSS、SAS及中医证候评分下降均显著优于安慰剂组(P<0.01),SDS评分组间无差异(P>0.05),未观察到严重不良事件。
要点
- 桂枝茯苓丸可显著减轻热灼血瘀证原发性痛经患者的疼痛强度。
- 该药还可改善痛经症状、焦虑状态及中医证候评分。
- 治疗期间未观察到严重不良事件,安全性较好。
核心结论
- 桂枝茯苓丸可显著减轻热灼血瘀证原发性痛经患者的月经疼痛严重程度,且无明显不良反应。
研究设计与样本
- 随机、双盲、安慰剂对照试验,筛查353例,随机分配128例,121例完成全部治疗和随访。
- 干预为桂枝茯苓丸或安慰剂每日两次,治疗3个月经周期,随访3个月。
主要发现
- 在意向性分析(FAS)和符合方案分析(PPS)中,桂枝茯苓丸组从基线至第6个月VAS疼痛评分下降均显著大于安慰剂组(P<0.01)。
- 桂枝茯苓丸组CMSS、SAS及中医证候评分下降均大于安慰剂组(P<0.01)。
- 两组SDS评分无差异(P>0.05)。
- 未观察到严重不良事件。
关键数值与推荐
- 主要结局为基线至第6个月VAS疼痛评分变化。
- 次要结局包括CMSS、SAS、SDS及中医证候量表从基线至第6个月的变化。
临床怎么用
- 对于热灼血瘀证原发性痛经患者,可考虑使用桂枝茯苓丸以减轻疼痛和改善相关症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Guizhi Fuling Wan (GFW) is one of the most widely known traditional Chinese medicine (TCM) formulations that has long been used in China for the treatment of primary dysmenorrhea (PD). However, the quality of evidence is limited and there are few studies on specific TCM syndromes of GFW for PD. AIM OF THE STUDY: To evaluate the efficacy and safety of GFW on PD patients with the heat-burning blood-stasis syndrome. MATERIALS AND METHODS: This was a randomized, double-blinded, placebo-controlled trial. Eligible patients were recruited and randomly assigned to one of two groups to receive GFW or the placebo twice daily for three menstrual cycles with a 3-month follow-up. The primary outcome was the baseline-to-month 6 change in pain intensity measured by a Visual Analog Scale (VAS). The secondary outcomes included the changes in the Cox Menstrual Symptom Scale (CMSS), the Self-rating Anxiety Scale (SAS), the Self-rating Depression Scale (SDS), and the TCM syndrome scale from baseline to month 6. Additionally, adverse effect was assessed. RESULTS: A total of 353 patients were screened for eligibility and 128 were randomly assigned, of whom 121 completed all treatments and follow-ups. In both the full analysis (FAS) and the per-protocol analysis (PPS), the VAS score of pain intensity decreased significantly more in the GFW group than in the placebo group from baseline to month 6 (P < 0.01). Similarly, the decrease in CMSS, SAS and TCM syndrome scores was greater in the GFW group compared with the placebo group (P < 0.01). There were no differences in SDS scores between the two groups (P > 0.05). In addition, no serious adverse events were observed. CONCLUSION: Our findings revealed that GFW significantly alleviated the severity of menstrual pain in PD patients with the heat-burning blood-stasis syndrome without significant adverse effects.
引用
- Luo Y, Mao P, Chen P, et al. Effect of Guizhi Fuling Wan in primary dysmenorrhea: A randomized controlled trial. J Ethnopharmacol. 2023. PMID: 36746293. doi:10.1016/j.jep.2023.116247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。